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David J Diller, Mark Jarosinski,
Tomi K Sawyer & Joseph Audie
Interest in peptide drug discovery is surging. In the
past several years, numerous pharmaceutical and biotech
companies have committed considerable resources to
peptide-based drug discovery. In part, this is being fueled
by an increasing recognition that peptide drugs com-
bine many of the virtues of small molecules and pro-
teins, while minimizing several of their drawbacks, and
that peptides can potentially expand the druggable space
to include intracellular, extracellular and membrane-
associated protein–protein interactions. Moreover, pow-
erful new in vitro and in silico technologies and break-
throughs in our understanding of natural peptides have
emerged that provide peptide chemists with the tools and
insights they need to solve the various pharmacokinetic
problems that often plague peptide drug discovery efforts.
From stapled peptides, to highly versatile macrocyclic pep-
tides and disulfide-rich peptides, to other peptides with
various nonstandard chemistries, peptides are poised to
fulfill their promise of providing a drug class that strad-
dles the chemical space between small molecules and pro-
teins, ultimately resulting in transformational medicines
and improved clinical outcomes.
c© 2015 Future Science Ltd 9
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Owing to the marginal return on investment in recent years, there is a
pressing need to re-examine all aspects of drug discovery. One area that
has received renewed focus and significant investment is that of innovative
peptide technologies that may enhance transformational drug discovery.
This renewed interest in therapeutic peptides may be attributed to two
considerations. First, US FDA approval rates for peptides (23–26%) [1] are
significantly greater than that of small-molecules (∼13%) [2]. Although pep-
tides currently account for a relatively small fraction of approved drugs, the
approximately twofold increase in clinical success probability is an impor-
tant metric, especially given that clinical trial attrition rates account for high
overall R&D costs. The second consideration is the large physicochemical
gap between small molecules (<500 Da) and biologics (>5000 Da). This gap
has left a therapeutic gap that peptides and macrocycles have the poten-
tial to fill. Indeed, there is mounting evidence that peptides can be used
to tackle challenging targets, such as protein–protein interactions (PPIs),
where small-molecules have had limited success, and in modulating key
intracellular PPI targets peptides may outperform antibodies that have lim-
ited cell-penetration properties.
As the excitement around peptide drug discovery builds, it is imperative to
understand why in the 1980s and 1990s peptides first lost traction as devel-
opment candidates. Two key reasons for this loss in momentum included
their challenging pharmacokinetic (PK) properties and manufacturing costs.
PK challenges for peptides can include poor intestinal absorption, low pro-
teolytic stability and rapid renal clearance. However, it should be noted that
for some disease indications apparent PK drawbacks can be beneficial. In
addition, nature has solved numerous physiological and pharmacological
peptide PK problems. For example, some natural product peptides (dietary-
derived bioactive peptides) have been determined to be orally bioavailable
and many peptide toxins have remarkable stability profiles. Such examples
provide compelling evidence that peptides may be optimized into effective
and broadly active pharmaceutical agents.
The therapeutic gap & the key opportunity for peptides in drug
discovery: the example of class-B G-protein-coupled receptors &
protein–protein interactions
Class-B G-protein-coupled receptors (GPCRs) are extracellular targets of nat-
ural peptides and are important drug targets. The peptide ligands for GPCRs
are approximately 30 amino acids (AAs) long, with diffuse pharmacophoric
domains (e.g., calcitonin, glucagon, parathyroid hormone). Class-B GPCRs
are transmembrane proteins with an amino-terminal extracellular domain
and an intracellular domain. The characteristic amino-terminal extracellular
domain contains three conserved disulfide bonds and a conserved cleft for
10 www.future-science.com
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binding to the helical carboxyl-terminal region of many natural peptides. The
extracellular domain orients the amino terminus of the peptides towards
the transmembrane helical bundle, which is critical for receptor activation.
Typically, to act as an antagonist a molecule needs to bind the extracellular
domain. This is generally possible to do with a protein or peptide. How-
ever, given that most protein interactions involve large, relatively flat and
diffuse interactions surfaces, small-molecule antagonist approaches would
appear to be quite limited. To act as an agonist, a molecule must interact
with the extracellular domain and the transmembrane helical bundle – a
multidomain interaction that is difficult to mimic with small-molecules or
proteins. Thus, the natural peptide ligands of class-B GCPRs have proven
to be useful starting points for agonist lead optimization [3], as exemplified
by the glucagon-like peptide-1 receptor (GLP1R) agonist peptides exenatide
and liraglutide, which are used to treat Type II diabetes. Finally, more excep-
tional therapeutic strategies, such as targeting intracellular GPCR structures
and interactions, have shown unique potential for peptide drug discovery
versus small-molecule or protein strategies.
PPIs are challenging drug targets owing to the presence of large, diffuse
and essentially flat binding surfaces that are not easily interrogated by small
molecules. Several strategies have been used to design small molecules for
protein interaction interfaces, with different levels of success. Discontinuous
binding epitopes, often encountered in PPIs, have generally proven to be
intractable with small molecules. By contrast, such binding epitopes can
be fruitfully explored with peptides. And while proteins can modulate PPIs,
they are limited to extracellular PPIs. Peptides, on the other hand, can be
developed to modulate intracellular and extracellular PPIs. As demonstrated
below, peptides can also bind to shallow and extended protein pockets. Thus,
with peptides, PPI targets become more generally druggable; moreover,
allosteric modulation of PPIs, where the interaction is further compromised
by disease-related mutations, are likely more druggable with respect to
peptide strategies.
Increasing the viable drug space: the characteristics of peptide
binding sites
To quantify the extent to which peptides broaden the viable druggable space,
it is worth highlighting a recent analysis of peptide–protein co-crystal struc-
tures [4], which included 103 co-crystal structures of peptides (5–15 AAs)
bound to nonredundant proteins. Importantly, this analysis uncovered sev-
eral aspects of peptide–protein interactions that differed from those gen-
erally known for PPIs. First, peptide–protein interactions were observed to
pack more effectively than PPIs. This is not surprising given that peptide–
protein interfaces have significantly less buried surface area than PPIs. The
www.future-science.com 11
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The blue histogram represents the contact atoms of small molecules. The red
histogram represents the contact atoms of peptides. A heavy atom of the ligand was
considered a contact atom if it was within 4.5 Å of a heavy atom of the protein. The
metric used to define the depth of the pocket is concavity. Low values of concavity
indicate deep pockets, whereas high values for concavity indicate shallow superficial
pockets.
second, more surprising, difference was that the peptide binding induced
little change in the target protein’s binding site. This can be attributed to the
fact that peptides are disordered in solution and lose a significant amount
of entropy upon binding. This entropy loss is partly compensated for by pre-
organized protein-binding partners. Hence, there are important differences
between PPIs and protein–peptide interactions that may be exploited to
increase the viable drug space.
Peptide–protein binding sites are also very different from small-molecule
protein binding sites. To support this point, we performed a survey of co-
crystal structures found in the protein data bank (PDB): 150 protein:small-
molecule complexes and 150 protein:peptide complexes. We next calculated
the binding site concavity at each atom of the ligand in contact with the
protein. As Figure 1.1 shows, nearly all the contact atoms of small molecules
are bound in deep pockets, whereas nearly all the contact atoms of peptides
bind in superficial grooves. As a concrete example, we show in Figure 1.2
12 www.future-science.com
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Figure 1.2 Potential binding sites on the pseudo-kinase domain of Jak2.
A B
The purple spheres are points of low curvature – consistent with small-molecule
binding sites. The yellow spheres are points of high curvature – consistent with
peptide binding sites. (A) The ATP binding site. (B) Other potential peptide binding
sites. This is the face opposite the ATP binding site. The portion of the surface colored
in dark blue highlights a mutation, V617F, common to many hematological disorders.
the pseudo-kinase domain of Jak2. The ATP-binding site is clearly consis-
tent with small-molecule binding. There are, however, several additional
sites on this domain that are consistent with peptide binding. These sites
could potentially be sites for biologically relevant PPIs or sites for allosteric
modulation by peptides. Particularly for targets such as kinases, where the
primary functional site is highly conserved over a large family of proteins,
allosteric sites offer the potential to improve upon selectivity and ultimately
safety. Hence, peptides offer excellent molecular probes for exploring novel
as well as conventional protein surfaces and binding sites.
Peptide binding site identification
The above observations regarding peptide–protein binding sites open excit-
ing opportunities for peptide drug design. Given that more than 25% of the
human genome either has a publically available crystal structure or could
be readily modeled, there is significant interest in finding and annotating
potential peptide binding sites.
Numerous computational methods have been proposed to identify potential
peptide binding sites and residue hot spots on proteins; here, a few meth-
ods are highlighted. At one extreme are purely sequence-based approaches.
For example, Yip and coworkers proposed a method that uses covariance
www.future-science.com 13
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within multiple sequence alignments (MSAs) to identify potential functional
sites [5]. The key to this strategy is to identify correlated residue changes
within a MSA or pair of MSAs that suggest structural or functional rela-
tionships and potential interaction sites. PepSite offers an approximate
structure-based approach for locating potential peptide binding sites [6].
Specifically, this approach is based on two key principles: the recognition
that peptide binding sites are often enriched in localized hot spots; and the
calculation of spatial position-specific AA scoring matrices that are derived
from a training set of protein–peptide interactions that encode informa-
tion regarding preferred AA-binding preferences. Therefore, this approach
allows for the rapid identification of potential peptide binding sites by scan-
ning the protein surfaces with each AA. Finally, in a fully structure-based
approach, Lavi and coworkers adapted a method originally used for small-
molecule binding site identification [7]. The premise to this approach is that
the entire protein surface is scanned with 16 molecular fragments. The
critical fragment binding sites are then identified by clustering and contact
scoring, and after removing inaccessible sites, the candidate peptide binding
sites are correlated with those for which multiple fragment sites exist.
Novel peptide lead identification: peptide properties & in vitro phage
display screening
Having established the structural basis for how peptides can expand the
viable drug space, we now turn to the discovery of novel peptide leads
through the use of in vitro screening approaches. In vitro display and
library screening technologies can be used to rapidly generate peptide diver-
sity. Traditionally, the technique of phage display has been used to search
through vast numbers of peptides to discover bioactive peptides. Indeed,
approved drugs have been discovered using phage display e.g., Kalbitor
(Dyax, Burlington MA, USA).
Because it exploits the bacteriophage for peptide synthesis, phage display is,
however, limited in its use of nonstandard AAs. This is significant, as incor-
poration of non-natural functionality and various cyclization chemistries has
proven to be a powerful way of converting a peptide lead into a drug with
improved potency and PK properties. For example, cyclosporin – a naturally
occurring N-to-C-cyclized macrocyclic peptide – is composed of numerous
nonstandard AAs and is the only highly orally bioavailable approved peptide
drug. Nature, too, exploits cyclization in bioactive peptides (e.g., marine and
microbial macrocyclic peptides, depsipeptides and disulfide-rich peptides,
such as conotoxins and cyclotides). Importantly, successful examples from
these peptide families have led to promising drug development candidates.
Indeed, a conotoxin peptide has been approved to treat neuropathic pain
(Ziconotide) and the Craik group is using novel cyclization approaches to
14 www.future-science.com
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develop an orally bioavailable version of the drug [8]. In the near future,
optimizing natural peptides into viable drug leads will be accomplished
through the use of enhanced high-throughput biological screening, includ-
ing synthetic peptide libraries as well as in silico design and computational
screening methods.
Novel peptide lead identification: going beyond phage display
screening
Following lead identification, peptide chemists traditionally seek to explore
non-natural peptide space through strategies such as non-natural side-chain
substitution, N-alkylation and the engineering of backbone constraints to
address PK liabilities and improve biological potency. While powerful, such
systematic approaches have proven to be costly and time consuming. Per-
haps the biggest improvements in peptide drug discovery will come through
the use of improved in vitro display technologies that can efficiently incor-
porate non-natural AA side chains, nonstandard stereochemistries, methy-
lation and various cyclizations. In what follows, we elaborate such peptide
drug discovery that has benefited from the use of enhanced peptide display
and screening technologies.
Peptide lead identification & optimization using advanced display &
screening technologies: some recent examples
Although not a recent advancement in peptide-based drug discovery, mirror
image phage display is a display methodology that can be used to go beyond
the natural 20 AAs. As an example, the strategy of mirror image phage
display used by Kay and coworkers led to the discovery of potent D-peptide
inhibitors of gp41-mediated HIV entry (Figure 1.3A) [9].
Yamagishi and coworkers describe the application of a ribosome-expressed
library of non-natural cyclic peptides to the discovery of blockers of the
E2 ubiquitin ligase E6AP (Figure 1.3B) [10]. This work is groundbreaking
because it uses a biologically generated in vitro-displayed peptide library to
target a PPI otherwise deemed to be undruggable. The thioether cyclized
14-mer library (>1012 peptides) included five non-natural AAs and identi-
fied an initial lead that included one d-AA and four N-methyl AAs with a
Kd of 0.6 nM. Interestingly, when not cyclized the Kd dropped nearly 300-
fold. Furthermore, when the N-methyl AAs were replaced by their natural
analogs no binding was detected. As a second application of this technol-
ogy, Kawakami and coworkers screened a macrocyclic library against the
extracellular domain of the VEGF receptor (VEGFR) [11]. This resulted in the
discovery of several nanomolar inhibitors of VEGFR autophosphorylation
www.future-science.com 15
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and also showed that the newly discovered macrocycles blocked VEGFR sig-
naling via the protein–protein interactions between VEGF and the extracel-
lular domain of VEGFR. These peptide leads may offer significant selectivity
advantages over ATP-competitive small-molecule inhibitors of VEGFR.
A recent discovery of thrombin inhibitors demonstrates the successful appli-
cation of an mRNA display technique incorporating non-natural AAs into a
cyclic peptide library (Figure 1.3C) [12]. This pioneering work by Szostak
and coworkers demonstrates the advantages of using non-natural AAs.
The library incorporated eight natural and 12 non-natural AAs. The equiva-
lent library incorporating the 20 natural AAs was screened in parallel with
the non-natural library. Both libraries produced low nanomolar throm-
bin inhibitors. No similarity, however, was reported between the various
inhibitors. Furthermore, when the non-natural AAs were replaced with their
natural counterparts, the resulting peptides showed no activity.
A final example demonstrates the generation of greater diversity using
a chemical ‘post-translational’ modification strategy starting with a linear
phage display library. The library was designed to incorporate three cys-
teine residues, resulting in a global bicyclic structure. Ultimately, a library
of more than 109 bicyclic peptides was screened for inhibitors of human
urokinase-type plasminogen activator (Figure 1.3D) [13]. The most potent
peptide exhibited a Ki of 4 nM. As a control, they synthesized the equivalent
peptide with the cysteines replaced by serines, preventing cyclization. The
peptide potency decreased by approximately 4000-fold, further implicating
the importance of rigid templates in peptide drug discovery.
Engineering natural peptide scaffolds
Numerous studies have exploited the remarkable characteristics of the
cyclotide family of peptides [14]. Briefly, the cyclotides are a family of
naturally-occurring disulfide rich peptides. They are unusually stable relative
to peptides of comparable size. This enhanced stability is often attributed
to a cyclic cysteine knot, which is composed of three disulfide bonds and
an N-to-C-cyclized backbone. The cyclotides have six cysteine loops, four of
which are amenable to sequence changes. Several groups have altered the
sequence of one of these loops to that of a known bioactive peptide, thereby
creating a cyclotide with new biological activity. As an example, Wong and
coworkers replaced loop 6 of the cyclotide kalata B with a nine-residue
bradykinin antagonist (Figure 1.3E) [15]. This resulted in a hybrid peptide
with bradykinin antagonist properties and the enhanced PK properties of a
cyclotide. Ultimately, the peptide was shown to be orally bioavailable.
Floudas and coworkers have developed a computational methodology to
improve biological activity by stabilizing the active conformation of a peptide
18 www.future-science.com
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through residue replacement [16]. Briefly, given desired C–C distances,
they used a coarse grain approach to select sequences most likely to stabilize
the conformation. The sequences were subjected to further calculations to
calculate the extent to which a sequence would stabilize a target conforma-
tion. In their most recent application, they applied the method to the design
of agonists, partial agonists and antagonists of the complement component
3a receptor (C3aR) [17]. Since the structure of C3aR is unknown, they applied
the design method starting from the structure of the C-terminal 15 AAs of
C3a. Importantly, they were able to improve a 170 nM agonist with 38%
maximal stimulation into a 25 nM agonist with a 72% maximal stimulation.
In another example of data-driven peptide design, the approach of anal-
ysis of correlated mutations was applied to the discovery of biologically
active peptides [18]. Using this method, several bioactive helical peptides
were identified. For example, a shortened version of gp96 that signifi-
cantly blocked the production of several chemokines in lipopolysaccharide-
stimulated peripheral blood mononuclear cells was identified. The peptide
was also shown to be active in vivo in a mouse model. A second helical
peptide, designed from clusterin, was shown to inhibit the growth of the
human lung carcinoma cell line A49 with an IC50 of 0.95 nM. Finally, a series
of peptides were designed from the angiopoietin family to disrupt the helix–
helix interactions critical for the activity of the angiopoietin proteins [19].
Out of 20 peptides tested, 11 showed significant antiangiogenic activity; the
peptides also showed in vivo antiangiogenic activity.
The work of Schepartz and coworkers is noteworthy with respect to
the design of a novel peptide agonist of the GLP1R, a class B GPCR
(Figure 1.3F) [20]. As a starting point for their investigation, they exploited the
observation that -peptides can mimic -helices. In addition, they exploited
the knowledge of the binding and activation mechanism of exendin-4, a
GLP-1 peptide agonist. Exendin-4 is 30 AA long and consists of a C-terminal
helix and a disordered N-terminus. The helix binds the extracellular domain
of GLP1R; the N-terminus is critical for activation. Initially, a -helix was
designed to mimic the C-terminal helix of exendin, resulting in 2 -helicies
that competed effectively for exendin-4 binding. The -peptides were then
linked to the N-terminus of GLP-1 via a PEG linker, and a lead peptide having
a half maximal effective concentration (EC50) of approximately 1 M was
identified.
As a final example of peptide engineering, the work of Sawyer and coworkers
on stapled -helical peptides shows the successful lead optimization of a
dual inhibitor of MDM2 and MDMX with potent activities in vitro and in
vivo [21]. The project started with a phage peptide that had a high affinity for
binding to MDM2 and MDMX. Several modifications of the stapled analog
led to an optimized stapled peptide analog, ATSP-7041, which was shown
www.future-science.com 19
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to exhibit potent cellular activity and robust cellular uptake which were
correlated with its amphipathicity, topochemical and solubility properties.
The importance of conformation in determining peptide properties &
function
A challenging aspect of understanding the behavior of peptides is conforma-
tion. Small molecules typically have approximately 10–15 rotatable bonds.
A peptide of only 15 AAs can easily eclipse 50 rotatable bonds. This greater
flexibility allows peptides to display multiple faces of which some may be
critical for biological function, while others may deleterious to such activ-
ity. As mentioned above, peptide conformational flexibility can also impede
high-affinity binding. Hence, cyclization is often used to promote a desired
conformation and minimize undesirable conformations. Several examples of
how cyclization can affect biological activity were given in the preceding sec-
tions. Here, we focus on the critical role conformation plays in determining
other peptide properties.
Conformational flexibility is increasingly recognized as important for cellu-
lar permeability [22]. Nevertheless, our current understanding of peptide
cellular penetration is in its infancy. Beck and coworkers reported two con-
formational families of N-methylated cyclo(d-Ala-Ala5) analogs as putative
templates for cell permeability and with the potential for bioavailability [23].
Eight of 54 analogs showed significant Caco-2 permeability. Interestingly, the
data suggest that the permeability is not due to passive diffusion because
the peptides are not permeable in the artificial membrane permeability
(PAMPA) assay and the Caco-2 permeability does not correlate with polarity.
Thus, the differences in permeability were attributed to an active transport
mechanism. Lokey and coworkers provide evidence that conformational
flexibility plays a significant role in passive diffusion as well. They synthe-
sized nine diastereomers of cyclo[Leu-Leu-Leu-Pro-Tyr] and found nearly 2
log units difference in logP as measured in the PAMPA model [24]. The same
group showed excellent agreement between a computational comparison
of the conformational behavior of eight cyclic hexa- and hepta-peptides in
low versus high dielectric media compared with experimentally measured
PAMPA logP values [25]. While these results are with small peptides, we
expect that the impact of conformation on PK properties will be amplified
for larger peptides.
Using computation to proficiently enable novel peptide discovery
In a 2010 review article, we called for the synergistic use of computation,
chemistry and biology to enable novel peptide drug discovery; other groups
have expanded on that call [26,27]. Advantages of computational methods
include quick turnaround, relatively low operational costs, the calculation
20 www.future-science.com
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of static and dynamic structural models and the calculation of energetic
quantities. Moreover, in silico methods can be expanded to include exotic
peptide chemistries, including nonstandard side chains, N-methylation, ter-
mini modifications, -peptides and various cyclizations. Some disadvantages
include force field and scoring function inaccuracies and imperfect confor-
mational search algorithms. In a previous section, we discussed the use of
computational methods to identify potential peptide binding sites. Here we
explore other uses of computation in peptide drug discovery.
The 2010 review article seems to have stimulated interest and several promi-
nent groups and companies are now reporting results for virtual peptide
docking. For example, researchers associated with the Rosetta project have
reported results for the peptide docking program, FlexPepDock [28]. Simi-
larly, researchers at Schrodinger recently reported the results of a peptide
docking study using a modified version of the docking program Glide [29], and
researchers at the University of Utrecht (The Netherlands) have described
their peptide docking program Haddock [30]. Given the correct binding site,
these programs can reproduce co-crystallized binding modes in the top 10
poses approximately 30–50% of the time starting with an apoprotein struc-
ture. The biggest difference between the results with peptides and small
molecules is the amount of CPU time needed. For small molecules the times
involved are often seconds to minutes, whereas the CPU times for peptides
can be in the order of days to weeks depending on the size of the peptides.
For problems such as identifying the binding mode for a known binding pep-
tide this amount of CPU time is trivial. For peptide discovery work, where
scientists are often interested in evaluating massive numbers of peptides,
the CPU requirements become the limiting factor.
Novel computational methods have also been developed for predicting
the 3D structures of linear and cyclic peptides with up to approximately
30 AAs [31,32]. These methods are, however, limited by their use of knowl-
edge extracted from structures in the PDB. This limits their ability to func-
tion with important families of non-natural AAs. We have developed an
alternative to such knowledge-based approaches. Briefly, our approach
(CMDpeptideSM, CT, USA) calculates conformational ensembles using an
optimized Monte Carlo algorithm and rank-orders the conformations using
an optimized, physics-based scoring function. In most cases, CMDpeptideSM
can locate distinctly near-native structures. We illustrate some results of our
method in Figures 1.4–1.6; where possible, we have included cyclic peptides
and peptides incorporating non-natural AAs. For example, Figure 1.5 shows
the results with cyclosporin and Figure 1.6 shows results with two naturally
occurring disulfide-rich peptides, uroguanylin and an -conotoxin, and a
stapled -helix.
www.future-science.com 21
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Figure 1.4 The overall results of CMDpeptideSM to identify native conformations on


















The different colors indicate whether the peptide structure is from an x-ray co-crystal
structure (black), a linear NMR structure (red) or cyclic NMR structure with one
(green), two (magenta) or three (blue) disulfide bonds. The RMSD is the lowest RMSD
found within the full ensemble generated and is given in units of Å.
RMSD: Root-mean-square deviation.
Indeed, we have developed a versatile, multimodule, fully integrated, com-
putational peptide drug discovery platform called CMDinventusSM, of which
CMDpeptideSM is a single module. Unlike other approaches, CMDinventusSM
is rigorously physics-based, has been developed from the ground-up to
address the peptide discovery problem and has been parameterized to work
with proteogenic and nonproteogenic peptide chemistries. CMDinventusSM
has been and is being used to design multiple lead series for disparate
protein-protein interaction targets. CMDinventusSM can be readily config-
ured to perform massive in silico natural and non-natural peptide screening
experiments and combined with in vitro technologies to make our vision of
synergistic peptide drug discovery a fruitful reality.
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(A) The sequence of cyclosporin. The sequence depiction is as described in Figure 1.3. (B) A
comparison of the two conformations from co-crystal structures. The conformation in green is
cyclosporin as bound to cyclophillin A (1cwa). The conformation in magenta is cyclosporin as bound to
an antibody. (C) The closest conformation to the conformation bound to cyclophillin A. (D) The closest
conformation to that bound to the antibody. The two conformations in cyan are the closest from the
CMDpeptideSM conformational ensemble to the given bound conformation. The RMSD between the
two bound conformations (A) is 1.3 Å while the RMSDs between the nearest computationally
generated conformation (B) and (C) are 0.91 and 0.95 Å, respectively.
Summary & conclusion
The renewed excitement around peptide drug discovery is both genuine
and well justified. Peptides offer an opportunity to target novel regions of
biological space, for example, intracellular PPIs, not suitable for either small
molecules or antibodies. Even with the advent of display technologies capa-
ble of incorporating more non-natural functionality, the challenge of using
peptides to transform drug discovery should not be underestimated. Indeed,
as the numbers of possible cyclizations and non-natural AAs increases, dis-
play technology will only be able to scratch the surface in terms of the
potential exploitable peptide chemical space. To fully exploit peptides for
drug discovery, it will be necessary to combine the best of existing in sil-
ico and in vitro approaches. For example, through the use of computation,
display technologies could be focused on the scaffolds and side chains that
achieved an optimized pharmacophore to a particular therapeutic target,
including the possibility of designing multitarget specificity. Unquestion-
ably, the importance of PK, including protease stability, distribution, cell
penetration, toxicity and immunogenicity, must be considered early in the
peptide drug discovery process. As our understanding of these phenomena
improves, the opportunity to harness predictive knowledge from leveraging
www.future-science.com 23
Diller, Jarosinski, Sawyer & Audie
Figure 1.6 Three macrocyclic peptides.
1uya: Uroguanylin – RMSD = 1.7 Å 1b45: α-conotoxin – RMSD = 1.1 Å
A B
3v3b: a stapled α-helix – RMSD = 1.0 Å
C
In all cases, the green conformation is the experimentally observed conformation
either from an NMR structure or a co-crystal structure and the magenta conformation
is that from the CMDpeptideSM ensemble closest to the native conformation. (A)
Uroguanylin (PDB code 1uya; RMSD: 1.7 Å). (B) An -conotoxin (pdb code 1b45;
RMSD: 1.1 Å). (C) A stapled -helix (pdb code 3v3b; RMSD: 1.0 Å).
RMSD: Root-mean-square deviation.
the structure–property relationships of peptides will fulfill the promise of
innovative technologies and development of breakthrough medicines.
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Summary
 There is a large physiochemical and biological gap between small molecules and antibodies, a gap
that peptides have the potential to fill.
 The key challenges for peptides to become drugs are largely pharmacokinetic, including oral
bioavailability, cellular penetration, proteolytic stability and renal clearance.
 The key to addressing the pharmacokinetic problems associated with peptides is the incorporation
of more non-natural functionality such as D-amino acids, N-methylation and cyclization.
 Understanding the complex conformational behavior of peptides is critical for understanding
many of their properties and ultimately for engineering desirable properties into the next
generation of peptide-based drugs.
 To fully exploit peptides for transformational drug discovery, it will be necessary to integrate the
most proficient of both in silico and in vitro methodologies.
Key terms
Peptide pharmacokinetics: the key pharmacokinetic (PK) challenges with peptides are
proteolytic stability, cellular penetration and renal clearance. This
differs from small molecules, which encounter cytochrome P450
metabolism and idiosyncratic toxicity.
Peptide conformation: the complex conformational behavior of peptides is another critical
difference from small molecules. Conformation is crucial for a
peptide’s pharmacokinetic and pharmacologic behavior. Peptides
can adopt several different faces, each of which could be
responsible for a different biological activity or characteristic.
Non-natural functionality: the key to addressing many of the shortcomings of peptides is to
incorporate non-natural functionality. This includes cyclization,
D-amino acids, N-methyl amino acids and non-natural side chains.
Display technology: includes any technology that relies on a biological mechanism to
synthesize and display a large library of peptides for screening
against pharmaceutical targets. This includes classic phage display
and the more recent development of mRNA display technologies
that have allowed the incorporation of significantly greater
non-natural functionality in the resulting libraries.
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